OKYO Pharma FY26 net loss widens to $8.95 million

• OKYO Pharma posted a net loss of USD 8.95 million, widening from USD 4.71 million a year earlier.
• Total operating expenses rose to USD 8.5 million from USD 7.09 million, as general and administrative costs climbed 38.3% to USD 6.69 million.
• Research and development spending fell 19.7% to USD 1.81 million, due to the settlement of patent invoices for Bam8 and Chemerin.
• Net cash used in operating activities increased to USD 5.94 million from USD 1.81 million, while cash and cash equivalents plus short-term investments totaled USD 20.59 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OKYO Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-033847), on July 20, 2026, and is solely responsible for the information contained therein.